The impact of thrombopoietin and related Mpl-ligands on transfusion medicine.
Farese
A M
AM
Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
Schiffer
C A
CA
MacVittie
T J
TJ
D000818:Animals; D001792:Blood Platelets / Q000166:cytology; D001803:Blood Transfusion; D002986:Clinical Trials as Topic; D006405:Hematology; D006801:Humans; D008533:Megakaryocytes / Q000166:cytology; D009363:Neoplasm Proteins; D010976:Platelet Count / Q000187:drug effects; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011518:Proto-Oncogene Proteins / Q000502:physiology; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D011994:Recombinant Proteins / Q000627:therapeutic use; D013926:Thrombopoietin / Q000502:physiology* / Q000627:therapeutic use
D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D011994:Recombinant Proteins; C103117:polyethylene glycol-recombinant human megakaryocyte growth and development factor; C082218:MPL protein, human; D011092:Polyethylene Glycols; D013926:Thrombopoietin